Current anti-IL-17A biotherapies (e.g. Secukinumab or Ixekizumab) have shown their effectiveness to control some chronic inflammatory disorders, such as rheumatoid arthritis [reviewed in (71–73)]. This evidence concerns the gene IL17A and rheumatoid arthritis.